{"id":69457,"date":"2026-07-07T21:43:29","date_gmt":"2026-07-07T21:43:29","guid":{"rendered":"https:\/\/www.oxfordcorp.com\/?p=69457"},"modified":"2026-07-07T21:44:58","modified_gmt":"2026-07-07T21:44:58","slug":"artificial-intelligence-in-drug-discovery-accelerate-the-path-from-bench-to-bedside","status":"publish","type":"post","link":"https:\/\/www.oxfordcorp.com\/nl-d\/insights\/blog\/artificial-intelligence-in-drug-discovery-accelerate-the-path-from-bench-to-bedside\/","title":{"rendered":"Artificial Intelligence in Drug Discovery:\u00a0Accelerate the Path from Bench to Bedside\u00a0"},"content":{"rendered":"

Drug discovery has always depended on\u00a0high-stakes decisions with incomplete information,\u00a0necessitating\u00a0a faster, smarter model. Today, artificial intelligence is giving life sciences organizations a more powerful way to connect biological, chemical, clinical, and real-world data, turning fragmented evidence into clearer signals for product development.<\/span>\u00a0<\/span><\/p>\n

By integrating biomedical data,\u00a0validating\u00a0stronger targets,\u00a0screening\u00a0and designing molecules virtually, predicting safety and efficacy earlier, and\u00a0optimizing\u00a0clinical trials, AI can help teams reduce avoidable failure and accelerate the path from bench to bedside.<\/span>\u00a0<\/span><\/p>\n

This is an urgent need, with drug development\u00a0remaining\u00a0long, expensive, and\u00a0high\u00a0risk. A\u00a0<\/span>2025\u00a0<\/span>JAMA\u00a0Network Open<\/span><\/i>\u00a0economic evaluation<\/span><\/a>\u00a0of drugs approved by the FDA in 2019\u00a0estimated median\u00a0and mean\u00a0R&D\u00a0costs\u00a0of $708\u00a0million and\u00a0$1.31\u00a0billion, respectively,\u00a0after adjusting for cost of capital and discontinued development efforts. Additionally,\u00a0a\u00a0<\/span>Pharmacoeconomics<\/span><\/i>\u00a0review<\/span><\/a>\u00a0found estimates\u00a0ranging from $161 million to\u00a0$4.54 billion\u00a0per new molecular entity.<\/span>\u00a0<\/span><\/p>\n

AI does not replace wet-lab experimentation, clinical evidence, or regulatory judgment. Its value lies in strengthening the decisions that shape each stage of development, helping R&D teams ask better questions\u00a0earlier in the process, prioritize stronger hypotheses, and focus resources on candidates with clearer biological and translational rationale.<\/span>\u00a0<\/span><\/p>\n

Where AI Fits Across the Drug Discovery and Development Lifecycle<\/span>\u00a0<\/span><\/h2>\n

AI creates the most value when\u00a0it is\u00a0embedded across the lifecycle rather than deployed as a\u00a0point\u00a0solution. The\u00a0<\/span>FDA\u2019s 2025 discussion paper<\/span><\/a>\u00a0describes AI\/ML\u00a0use cases across discovery, nonclinical research, clinical research, post-market safety, and advanced pharmaceutical manufacturing.<\/span>\u00a0<\/span><\/p>\n

In early\u00a0discovery, AI can integrate genomics, transcriptomics, proteomics, single-cell data, pathway databases, literature, and real-world evidence to\u00a0identify\u00a0disease mechanisms and prioritize druggable targets. Graph neural networks, causal inference, and knowledge graphs help assess biological relevance, genetic support, tractability, and clinical connection.<\/span>\u00a0<\/span><\/p>\n

During hit discovery and lead optimization,\u00a0machine learning\u00a0can support virtual screening, molecular docking, QSAR modeling, active learning, and generative molecule design. These approaches help\u00a0teams\u00a0search\u00a0chemical space while balancing potency, selectivity, solubility, permeability, metabolic stability, synthetic accessibility, and toxicity risk.<\/span>\u00a0<\/span><\/p>\n

In preclinical and clinical development, AI can support several high-value activities:<\/span>\u00a0<\/span><\/p>\n